Currently, i.t. STING agonist therapy is generally recognized to increase the production of type I interferon in tumours, which promotes CD8+ T cell priming and infiltration into the tumour, eventually converting immunologically “cold” tumours to “hot” tumours9,14,20. This evidence concerns the gene STING1 and neoplasm.